LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
=== COVID-19 pandemic === On 20 January 2020, Xi commented for the first time on the emerging COVID-19 pandemic in Wuhan, and ordered "efforts to curb the spread" of the virus. He gave premier Li Keqiang some responsibility over the COVID-19 response, in what has been suggested by The Wall Street Journal was an attempt to potentially insulate himself from criticism if the response failed. The government initially responded to the pandemic with a lockdown and censorship, with the initial response causing widespread backlash within China. Xi met with Tedros Adhanom Ghebreyesus, the director-general of the World Health Organization (WHO), on 28 January. Der Spiegel reported that in January 2020 Xi pressured Tedros Adhanom to hold off on issuing a global warning about the outbreak of COVID-19 and hold back information on human-to-human transmission of the virus, allegations denied by the WHO. On 5 February, Xi met with Cambodian prime minister Hun Sen in Beijing, the first foreign leader allowed into China since the outbreak. After the COVID-19 outbreak got under control in Wuhan, Xi visited the city on 10 March. After getting the outbreak in Wuhan under control, Xi has favoured what has officially been termed "dynamic zero-COVID policy" that aims to control and suppress the virus as much as possible within the country's borders. This has involved local lockdowns and mass-testing.
== History and disclosure == Novichok agents were designed as part of a Soviet program codenamed Foliant. Five Novichok variants are believed to have been adapted for military use. The most versatile is A-232 (Novichok-5). Novichok agents have never been used on the battlefield. The UK government determined that a Novichok agent was used in the poisoning of Sergei and Yulia Skripal in Salisbury, Wiltshire, England in March 2018. This was unanimously confirmed by four laboratories around the world, according to the OPCW. Novichok was also involved in the poisoning of a British couple in Amesbury, Wiltshire, four months later, believed to have been caused by residual nerve agent discarded after the Salisbury attack. The attacks led to the death of one person, left three others in a critical condition from which they recovered, and briefly hospitalised a police officer. The Russian government denies producing or researching agents "under the title Novichok". In September 2020, the German government said that opposition figure and anti-corruption activist Alexei Navalny, who was evacuated from Omsk to Berlin for treatment in late August after becoming ill during his flight, was poisoned by a Novichok agent. Novichok has been known to most Western intelligence services since the 1990s, and in 2016 Iranian chemists working at a university in Tehran synthesised five of the seven Novichok agents for analysis and produced detailed mass spectroscopy data which was added to the OPCW's Central Analytical Database.
BRD-6929, also widely known as "compound 60" (Cpd-60 or Cmpd60), is a histone deacetylase (HDAC) inhibitor which is used in scientific research. It has been described in the past as the prototypical selective HDAC1 and HDAC2 inhibitor. However, subsequent findings suggest that BRD-6929 may not actually be selective for HDAC1 and HDAC2 over HDAC3.
30 October – Dairy company Fonterra's farmer shareholders vote to authorise the sale of several brands including Mainland and Anchor to French company Lactalis. New Zealand First leader and cabinet minister Winston Peters denounces the sale as "short-sighted." Health New Zealand has confirmed two new cases of measles, bringing the total number of active cases to 13. The number of close contacts has risen to 2,142. 31 October: The Waitangi Tribunal rules that the Citizenship Act 1977 breaches the Treaty of Waitangi by limiting eligibility for citizenship by descent for Māori people to one generation and failing to recognise Māori as tangata whenua ("People of the Land"). A power outage affects 23,000 homes and businesses in the Far North District. Auckland Grammar School instructs Years 9 and 10 students to remain at home after a student tested positive for measles.
Supplementary motor area A region of the medial frontal cortex involved in the planning and coordination of complex, internally generated movements. The SMA contributes to motor sequence initiation, bimanual coordination, and motor imagery. Synapse The junction between two neurons (or between a neuron and another cell) where information is transmitted via neurotransmitters or electrical signals. Synaptic cleft The small space between the presynaptic and postsynaptic neurons across which neurotransmitters are released. Synaptic plasticity The ability of synapses to strengthen or weaken over time, based on activity levels. It underlies learning and memory. Synaptogenesis The formation of new synapses between neurons. It occurs extensively during development and continues throughout life in certain brain regions. Synaptopathy A disorder of synaptic function, often implicated in neurodevelopmental and neurodegenerative diseases such as autism and Alzheimer’s disease. Syringomyelia A condition in which a cyst forms within the spinal cord, potentially damaging nerve fibers and leading to pain, weakness, and sensory loss.
Sources: en.wikipedia.org
=== Physical intervention === The most widely used therapeutic intervention is positive airway pressure whereby a breathing machine pumps a controlled stream of air through a mask worn over the nose, mouth, or both. The additional pressure holds open the relaxed muscles. There are several variants:
== Side effects == Side effects of LGD-4033 may include headache and dry mouth. LGD-4033 has been found to dose-dependently decrease levels of total testosterone, free testosterone, follicle-stimulating hormone (FSH), sex hormone-binding globulin (SHBG), HDL cholesterol, and triglycerides, while not affecting levels of luteinizing hormone (LH), total cholesterol, LDL cholesterol, or prostate-specific antigen (PSA). Due to the decreased ratio of HDL cholesterol to LDL cholesterol, LGD-4033 could theoretically increase the risk of heart attack and stroke. Elevated liver enzymes, such as increased levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT), have not been reported with LGD-4033 in the few conducted clinical trials thus far. However, multiple case reports of hepatotoxicity with LGD-4033 in the setting of non-medical use have been published. LGD-4033 and other SARMs are largely uncharacterized in terms of their potential for masculinizing effects, for example in women. In addition, the effects and safety of high doses of LGD-4033 and other SARMs, which are often used in non-medical contexts, are unknown. Anecdotal reports of masculinization with black-market SARMs in women exist in online forums. The United States Food and Drug Administration (FDA) claims that "liver toxicity, adverse effects on blood lipid levels, and a potential to increase the risk of heart attack and stroke" are among the potential adverse health effects of SARMs including LGD-4033.
== Research == As of 2006, leuprorelin was under investigation for possible use in the treatment of mild to moderate Alzheimer's disease. A by mouth formulation of leuprorelin is under development for the treatment of endometriosis. It was also under development for the treatment of precocious puberty, prostate cancer, and uterine fibroids, but development for these uses was discontinued. The formulation has the tentative brand name Ovarest. As of July 2018, it is in phase II clinical trials for endometriosis.
=== High Point Media === After Phillips sold his majority interest in EAS, he concentrated on his writing and on promotion of his books through his publishing company, High Point Media, as well as Value Creation, a branch of EAS. Body for Life hit bookstores in 1999, and by 2003 it had sold 3.5 million copies in 24 languages. The book topped the charts in 11 different countries-including the United States, England, Japan, Australia, Greece and Finland. In 2004 USA Today named it among the Top 15 bestselling books of the past decade. In November 2003, Eating for Life: Your Guide to Great Health, Fat Loss and Increased Energy! was released. In the book Phillips offers his plan "to help inspire and guide even more people to improve their health and lift their quality of life to new heights." In February 2006, Phillips announced his "Great American Transformation Experience" (GATE) with a goal to transform America's fitness from world's worst to first within 10 years. On June 21, 2010, Phillips' latest book, Transformation: The Mindset You Need. The Body You Want. The Life You Deserve was released. A companion website, Transformation.com, that walks individuals through the transformation process was also updated. The site features a community dedicated to supporting its members' personal goals. On July 10, 2010, the book made the New York Times Best Seller list.
Sources: en.wikipedia.org
===== Colombia ===== In July 2023, Lula and Colombian president Gustavo Petro met in Leticia to discuss the details of an Amazon Cooperation Treaty Organization (ACTO) summit scheduled to take place a month later. Both presidents also discussed trade and defence between Colombia and Brazil. In April 2024, Lula visited Colombia and opened the 2024 Bogota International Book Fair alongside president Gustavo Petro. The two countries later signed six cooperation agreements regarding several topics including human trafficking. Lula and Petro also discussed the crisis in Venezuela.
== Medical use == Cyclofenil is used to treat menstrual disturbances and anovulatory infertility caused by insufficiency of the hypothalamic–pituitary–gonadal axis in women. It has also been used to treat menopausal symptoms. The medication is generally used at a dosage of 400 to 600 mg per day.
Absorbance Units Full Scale (AUFS) or Absorption Units Full Scale is a unit of absorbance intensity that denotes the output of a spectrophotometer. The acronym AUFS can also be written out as Absorbance Units per Full Scale Deflection. AUFS is an arbitrary unit of the maximum ultraviolet or visible light absorbance intensity measured by a detector. It can be used in chemical analysis to quantify components in a mixture, as each component's integrated peak area corresponds to their relative abundance. AUFS is given as a number ranging from 0 to 1, where a measurement of 1 AUFS indicates an absorbance reading of 1 at full deflection. Analytical chemistry Chromatography Spectroscopy
There are three known stable isotopes of oxygen (8O): 16O, 17O, and 18O. Radioisotopes are known from 11O to 28O (particle-bound from mass number 13 to 24), and the most stable are 15O with half-life 122.27 seconds and 14O with half-life 70.62 seconds. All remaining radioisotopes are even shorter in lifetime. The four heaviest known isotopes (up to 28O) decay by neutron emission to 24O, whose half-life is 77 milliseconds; 24O, along with 28Ne, have been used in the model of reactions in the crust of neutron stars. The most common decay mode for isotopes lighter than the stable isotopes is β+ decay to nitrogen, and the most common mode after is β− decay to fluorine.
Insulin pumps are a reasonable solution for some. Advantages to the person are better control over background or basal insulin dosage, bolus doses calculated to fractions of a unit, and calculators in the pump that may help with determining bolus infusion dosages. The limitations are cost, the potential for hypoglycemic and hyperglycemic episodes, catheter problems, and no "closed loop" means of controlling insulin delivery based on current blood glucose levels. Insulin pumps may be like 'electrical injectors' attached to a temporarily implanted catheter or cannula. Some who cannot achieve adequate glucose control by conventional (or jet) injection are able to do so with the appropriate pump. Indwelling catheters pose the risk of infection and ulceration, and some peoples may also develop lipodystrophy due to the infusion sets. These risks can often be minimized by keeping infusion sites clean. Insulin pumps require care and effort to use correctly.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.